Notes

The fund is called Catalyst Research and it has a size of 0 as of September 22, 2026, at 08:16:08 UTC. There are several news updates from various companies, including Telix Pharma on September 20, 2026, Mission Produce on September 8, 2026, ABM on September 8, 2026, and Roivant on September 8, 2026. Additionally, there are financial reports from UNFI on September 14, 2026, DRI on July 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, and WLTH on September 14, 2026. Evolution Petroleum announced its participation in upcoming investor conferences on September 21, 2026, and IPHA filed a 6-K report on September 17, 2026. The HTTP status codes for KGF, ASKUL, IPHAnews, and SOBI are 200, with corresponding hashes. The research notes conclude with a reminder to read originals and validate strong and new information, and to cash and reverify weak or absent information. There are specific instructions regarding IPHA and Sobi, and monitors to preserve. The sources and dates are listed in the job script and journal, and there are no orders.

The Catalyst fund is currently in research mode only, with a size of 0, as of September 22, 2026, at 07:46:05 UTC. The fund is tracking several stocks, including IONS, MIRM, GIS, EAT, and CAG. The Securities and Exchange Commission (SEC) filings for these stocks are available at the following links: IONS on September 4, 2026, MIRM on September 8, 2026, GIS on July 1, 2026, and EAT on September 17, 2026. A discovery note from Barclays on September 9, 2026, maintained an overweight rating on Ionis Pharmaceuticals and lowered the price target to $85. GIS had a conference and review on September 8, 2026, at 19:40 UTC, which has already passed. The fund is waiting for the earnings release from GIS on September 23, 2026, at 13:00 UTC. The baseline expectations for GIS are an EPS of $3.00-3.20 for fiscal year 2027, with organic growth of -1.5% to +0.5% and savings of $750 million. The fund is also tracking EAT, which had an investor day on September 17, 2026, and is scheduled to have an earnings call on October 28, 2026. The fund's strategy for EAT is to record and validate stronger organic cash growth, and to reverify weaker or absent growth. The fund has a frozen paper window from September 16 to September 21, and a calendar out-of-sample (OOS) performance of +0.567% and stress performance of -2.405%. The fund has chosen to review EAT on September 17, 2026, at 16:30 UTC, and will reverify the first news release on October 28, 2026. The fund's research is ongoing, with no automatic trades or orders, and will verify full pipelines and early news.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 22, 2026, at 07:01:05 UTC. The fund manager reviewed the following SEC filings: CHWY's 10-Q filing on September 9, 2026, ASO's 10-Q filing on September 9, 2026, and LOVE's 10-Q filing on September 10, 2026, as well as SFIX's 8-K filing on July 28, 2026. The manager also looked at the following news releases: SAIL's announcement on September 9, 2026, KFY's announcement on September 9, 2026, and LOVE's announcement on September 15, 2026. Additionally, the manager checked the FDA's website and found information about GRAL, including a meeting on September 23, 2026. The manager noted that the SEC filings may not be up to date with the latest news. The manager will review the following: new morning results on September 9 at 12:30, LOVE's results on September 10 at 12:30, and SFIX's results on September 24 at 12:30 after the September 23 AMC. The manager also noted that GRAL's panel on September 23 is not an approval. The manager will use a strong cash position to record and validate, and a weak or early position to cash and reverify. No automatic orders were made.

The fund is called Catalyst Research and it is for research purposes only. The size of the fund is 0 and the time of the update is September 22, 2026, at 04:16:06 UTC. There are several news updates from various companies, including Telix Pharma on September 20, 2026, Mission Produce on September 8, 2026, ABM on September 8, 2026, and Roivant on September 8, 2026. Additionally, there are financial reports from UNFI on September 14, 2026, DRI on July 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, and WLTH on September 14, 2026. Evolution Petroleum also announced its participation in upcoming investor conferences on September 21, 2026. Furthermore, there are HTTP status updates for KGF, ASKUL, IPHAnews, and SOBI. The research notes that IPHA had an update on September 17, 2026, and there is a conditional receipt for Sobi for Q1-2028. The monitors for 165, 168, 167, 137, and 22 are to be preserved. The sources and dates for the job script and journal are available, but there are no orders to be executed. The research concludes with a note to read the originals and validate the information, and to cash and reverify if the information is weak, absent, or contains an error.

A fund manager for the Catalyst research fund made some notes. The fund size is 0 and it is for research only. The notes were made on 2026-09-22 at 04:01:09. The manager looked at some receipts and archives from before 91108. The manager also looked at some SEC filings from HITI and BFRI on 2026-09-14. A news scan found the headline 'Dave & Buster’s Reports Second Quarter 2026' on September 14, 2026. The manager also looked at some reviews and data from TSM and CAN. The manager noted that all branches had improved organic cash and credible clinical evidence. The manager also looked at some information about EGTX, including a multifaceted news feed count of 48. The manager noted that BFRI had an ITC, which is a type of trade commission, and that a suspension had been lifted on September 1, 2026. The manager made a total of 11 notes, which are referred to as panels.

The Catalyst fund is currently in research mode only, with no active orders, as of September 22, 2026, at 03:31:06 UTC. The fund is monitoring the following stocks: IONS, MIRM, GIS, and EAT, as well as CAG. The fund has a size of 0. The Securities and Exchange Commission (SEC) filings for these stocks are available at the following links: IONS on September 4, 2026, MIRM on September 8, 2026, GIS on July 1, 2026, and EAT on September 17, 2026. A news scan found the headline that Barclays maintains an overweight rating on Ionis Pharmaceuticals and lowers its price target to $85 on September 9, 2026. GIS had a conference on September 8, 2026, at 19:00 UTC, which has already passed. The fund will review the replay. General Mills, the company behind GIS, will release its earnings on September 23, 2026, at 13:00 UTC, with a question-and-answer session, but the exact release time is unknown. The fund will review the earnings release. If GIS has stronger organic cash flow and guidance, the fund will record and validate the results. If the results are weaker or absent, the fund will reverify the cash flow. The fund does not have an automatic entry point, and the dates listed are for review purposes only, not for first news. The baseline for GIS is an EPS of $3.00-3.20 for fiscal year 2027, with organic growth of -1.5% to +0.5% and savings of $750 million. The fund had a frozen paper window from September 16 to September 21, with a calendar out-of-sample (OOS) return of +0.567% and a stress return of -2.405%. The fund will not retune past tests. EAT had an investor day on August 31, 2026, and the fund chose to review it on September 17, 2026, at 16:30 UTC. EAT also announced its earnings call date for October 28, 2026, but the hour and first release time are unknown. The fund will review the earnings call on October 28, 2026, at 16:30 UTC and reverify the first news. If EAT has stronger organic cash flow, the fund will record and independently validate the results. If the results are weaker or absent, the fund will reverify the cash flow. The fund has a frozen T5 holdout of -19.2065% and will not make automatic trades. The investor-day odds are untested, and static dates are not armed. The fund is monitoring four SEC filings, one discovery, two GIS events, and two EAT events, and will verify full pipelines and early news. The fund remains in research mode only, with no orders, as of September 22, 2026, at 03:31:08 UTC.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 22, 2026, at 03:01:05 UTC. The fund manager reviewed the following SEC filings: CHWY's 10-Q filing on September 9, 2026, ASO's 10-Q filing on September 9, 2026, and LOVE's 10-Q filing on September 10, 2026, as well as SFIX's 8-K filing on July 28, 2026. The manager also reviewed news from SAIL, KFY, and LOVE, which were released on September 9, 2026, and September 15, 2026. Additionally, the manager checked the FDA website for updates on GRAL, which has a meeting scheduled for September 23, 2026. The manager noted that the SEC filings may lag behind news and that reviews are scheduled for September 9, 12:30, for new morning results, September 10, 12:30, for LOVE, and September 24, 12:30, for SFIX, after the September 23 AMC. The manager also noted that the GRAL panel on September 23 is not an approval and that strong cash positions should be recorded and validated, while weak or early positions should be cashed and reverified. No automatic orders were placed.

The Catalyst Research fund has a size of 0 as of September 22, 2026, at 00:01:23 UTC. Recent news includes: TLX on September 20, 2026, about a partnership with ITM, AVO on September 8, 2026, about fiscal third-quarter financial results, ABM on September 8, 2026, about fiscal third-quarter results, and ROIV on September 8, 2026, about positive results from a study. There have been recent filings from UNFI on September 14, 2026, DRI on July 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, and WLTH on September 14, 2026. Additionally, EPM announced participation in upcoming investor conferences on September 21, 2026, and IPHA filed a 6-K on September 17, 2026. HTTP requests were successful for KGF, ASKUL, IPHAnews, and SOBI. Research is limited to reading originals and validating information. A conditional receipt for Sobi is expected by Q1 2028. Certain monitors, including 165, 168, 167, 137, and 22, will be preserved. The sources and dates are recorded in the job script and journal, and there are no orders at this time.

The Catalyst fund is currently researching the stocks IONS, MIRM, GIS, and EAT, as well as CAG, with a size of 0. The fund's status was updated on September 21, 2026, at 23:31:05 UTC. The fund manager has been reviewing SEC filings for these stocks, including IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on September 17. A news scan found the headline that Barclays maintains an overweight rating on Ionis Pharmaceuticals and lowers its price target to $85. The GIS conference was held on September 8 at 19:00 UTC, and the STATIC morning earnings call is scheduled for September 23. The fund manager is monitoring GIS's organic cash flow and guidance, and will reverify if the results are weaker or absent. The baseline for GIS's FY27 EPS is $3.00-3.20, with organic growth of -1.5% to +0.5% and savings of $750 million. The fund manager has also been reviewing EAT's investor day on September 17 and earnings call date on October 28. The fund manager will record and independently validate EAT's stronger organic cash flow, and reverify if the results are weaker or absent. The fund's research is ongoing, and no orders have been placed. The fund's status was updated again on September 21, 2026, at 23:31:07 UTC.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 21, 2026, at 22:46:03 UTC. The fund reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, LOVE on September 10, 2026, and SFIX on July 28, 2026. The fund also reviewed the following RSS feeds: SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 15, 2026. Additionally, the fund noted an FDA meeting for GRAL on September 23, 2026. The fund will review new morning results on September 9 at 12:30 UTC, LOVE on September 10 at 12:30 UTC, and SFIX on September 24 at 12:30 UTC after the September 23 AMC. The GRAL panel on September 23 is not for approval. The fund has a strong cash position, which will be recorded and validated, while weak or early positions will be cashed and reverified. No automatic orders were made.

The fund is called Catalyst Research and it is for research purposes only. The fund size is 0 and the time is 2026-09-21T20:01:04.141801+00:00. There are several news updates: TLX on Sunday, September 20, 2026, announced a partnership on the Telix Pharma website. AVO announced its fiscal 2026 third-quarter financial results on Tuesday, September 8, 2026, on the Mission Produce website. ABM reported its fiscal third-quarter 2026 results on Tuesday, September 8, 2026, on the ABM website. ROIV announced positive results from a study on Tuesday, September 8, 2026, on the Roivant website. There are also several financial reports: UNFI filed a 10-K report on September 14, 2026, DRI filed a 10-K report on July 24, 2026, PPIH filed a 10-Q report on September 9, 2026, MRK filed a 10-Q report on August 7, 2026, and WLTH filed a 10-Q report on September 14, 2026. EPM reported its fiscal fourth-quarter and full-year results on Tuesday, September 15, 2026, on the Evolution Petroleum website. IPHA filed a 6-K report on September 17, 2026. The HTTP status for KGF is 200 with a hash of 9ef4336aeb9528cc, for ASKUL is 200 with a hash of e6f0d85c03a37ce6, and for SOBI is 200 with a hash of 7569409d160b2a08. However, there was an error with IPHA news due to a ValueError. The decision is to preserve monitors 165, 168, 167, 137, and 22, and there are no orders. The IPHA update was on September 17, and the Sobi receipt is conditional on Q1 2028.

A fund manager reviewed notes from the Catalyst Research fund, which has a size of 0 and compact receipts. The notes originated from the PRE91108 archive and were last updated on 2026-09-21T19:46:16.559609+00:00. The manager reviewed 11 panels of information, including SEC filings for HITI and BFRI on 2026-09-14, a report from Dave & Buster's on September 14, 2026, and information about TSM, CAN, and EGTX. The manager also reviewed a report about BFRI's photodynamic therapy systems and a notice about the lifting of a suspension on September 1, 2026. The manager has completed the review of the panels, which included previews of the information, but notes that the originals should be read before taking any action.

The Catalyst fund is currently researching IONS, MIRM, GIS, and EAT, with a size of 0, as of September 21, 2026, at 19:16:05 UTC. The fund has reviewed SEC filings for IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on September 17. A news scan found the headline that Barclays maintains an overweight rating on Ionis Pharmaceuticals and lowers its price target to $85 on September 9. GIS had a conference and review on September 8 at 19:40 UTC, which has already passed. The fund is waiting for GIS's morning earnings on September 23, with a Q&A session at 13:00 UTC. The baseline for GIS's FY27 EPS is 3.00-3.20, with organic growth of -1.5 to +0.5% and savings of $750 million. The fund has a frozen paper window from September 16 to September 21, with a calendar return of 0.567% and stress of -2.405%. EAT had an investor day on September 17, and the fund is waiting for its earnings call on October 28. The fund will verify the full pipelines and early news for these stocks. The research is ongoing, with no orders placed as of September 21, 2026, at 19:16:08 UTC.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 21, 2026, at 18:31:04 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. The manager also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the manager looked at RSS feeds from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 15, 2026. The manager also checked the FDA website for information on GRAL, which had a meeting scheduled for September 23, 2026. The manager noted that the SEC filings may lag behind news and that reviews are scheduled for September 9 at 12:30 for new morning results, September 10 at 12:30 for LOVE, and September 24 at 12:30 for SFIX after the September 23 AMC. The manager also noted that the GRAL panel on September 23 is not for approval. The manager uses a system where strong cash positions are recorded and validated, while weak or early positions require cash reverification. No automatic orders were placed.

The fund is called Catalyst Research and it has a size of 0 as of September 21, 2026, at 15:46:05 UTC. There are several news updates: Telix Pharma announced a partnership on September 20, 2026, which can be found at https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/. Mission Produce announced their fiscal 2026 third-quarter financial results on September 8, 2026, which can be found at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial. ABM reported their fiscal third-quarter 2026 results on September 8, 2026, which can be found at https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results. Roivant announced positive results from the Phocus study of mosliciguat on September 8, 2026, which can be found at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat. There was an error reading the data for UNFI, MRK, and WLTH due to a ReadTimeout. Darden Restaurants filed their 10-K report on July 24, 2026, which can be found at 0000940944-26-000025/dri-20260531.htm. Perma-Pipe International filed their 10-Q report on September 9, 2026, which can be found at 0001437749-26-029988/ppih20260731_10q.htm. Evolution Petroleum reported their fiscal fourth-quarter and full-year results on September 15, 2026, which can be found at https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-reports-fiscal-fourth-quarter-and-full-0. IPHA filed a 6-K report on September 17, 2026, which can be found at 0001628280-26-062360/a6kseptember172026.htm. The HTTP requests for KGF, ASKUL, IPHAnews, and SOBI were successful, with hashes 9ef4336aeb9528cc, e6f0d85c03a37ce6, ef3293fd5ff26cb3, and 7569409d160b2a08, respectively. The research is ongoing, with a focus on reading originals and validating information for strong and new data, and cashing and reverifying weak or absent data. There is a note about IPHA on September 17 and a conditional receipt for Sobi for Q1 2028. The monitors for 165, 168, 167, 137, and 22 are preserved. The sources and dates can be found in the job script and journal. There are no orders.

The Catalyst fund is currently researching IONS, MIRM, GIS, and EAT, with no current size, as of September 21, 2026, at 15:01:08 UTC. The fund has reviewed SEC filings for IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on September 17. On September 9, Barclays maintained an overweight rating on Ionis Pharmaceuticals, lowering its price target to $85. GIS had a conference on September 8, which has already passed. The fund is waiting for GIS's earnings release on September 23. The baseline for GIS's fiscal year 2027 is an EPS of $3.00-3.20, with organic growth of -1.5 to +0.5%, and savings of $750 million. The fund has frozen its paper window from September 16 to September 21, with a calendar out-of-sample performance of +0.567% and stress performance of -2.405%. EAT had an investor day on September 17 and is scheduled to have an earnings call on October 28. The fund will review EAT's performance, with stronger organic cash flow leading to record and independent validation, and weaker or absent cash flow leading to re-verification. The fund has not set any automatic trades and will verify full pipelines and early news for all stocks.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 21, 2026, at 14:16:13 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. The manager also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the manager looked at news releases from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 15, 2026. The manager also checked the FDA website and found information about a meeting on September 23, 2026. The manager will review new results on September 9 at 12:30 UTC, LOVE results on September 10 at 12:30, and SFIX results on September 24 at 12:30 after the September 23 AMC. The GRAL panel on September 23 is not an approval. The manager will use a record and validation process for strong cash positions and a cash and reverification process for weak, early, or absent positions. No automatic orders were made.

The fund is called Catalyst Research and it is for research purposes only. The fund size is 0 and the time is 2026-09-21T11:46:09.530618+00:00. There are several news updates from different companies, including Telix Pharma on Sunday, September 20, 2026, Mission Produce on Tuesday, September 8, 2026, ABM on Tuesday, September 8, 2026, Roivant on Tuesday, September 8, 2026, and Evolution Petroleum on Tuesday, September 15, 2026. There are also financial reports from UNFI on September 14, 2026, DRI on July 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, and WLTH on September 14, 2026. Additionally, there are updates from IPHA on September 17, 2026. The HTTP status codes for KGF, ASKUL, IPHAnews, and SOBI are 200, with corresponding hashes. The research notes end with the instruction to preserve certain monitors and not to place any orders.

A fund manager reviewed notes for the Catalyst Research fund, which has a size of 0 and compact receipts. The origins of the fund are in the PRE91108 archive, and the review was done on 2026-09-21T11:46:09.444691+00:00. The manager looked at various panels, including SEC filings for HITI and BFRI on 2026-09-14, and a report from Dave & Buster's on September 14, 2026. The manager also reviewed chosen UTC reviews, including one for TSM on September 10, and a new announcement from CAN on September 8. Additionally, the manager looked at information on EGTX, including a multifaceted news feed count of 48 and a latest update on September 11. The manager also reviewed conferences and a suspension lift for BFRI on September 1. The review consisted of 11 panels, with a raw sha of 23e5b826f0fca488718841d3174775290b7d737b9982ed1933d9f67ce5a83542.

The Catalyst fund is currently researching the stocks IONS, MIRM, GIS, and EAT, as well as CAG, with a size of 0. The fund's status was updated on September 21, 2026, at 10:46:06 UTC. The fund manager has been reviewing SEC filings for these stocks, including IONS on September 4, MIRM on September 8, GIS on July 1, and EAT on September 17. A discovery was made on September 9 that Barclays maintains an overweight rating on Ionis Pharmaceuticals, but lowers its price target to $85. The GIS company had a conference on September 8, and its earnings will be released on September 23. The fund manager will review the earnings and verify the cash flow and guidance. The baseline for GIS is an EPS of $3.00-3.20 and organic growth of -1.5 to +0.5%. The fund manager also reviewed EAT's investor day on September 17 and its upcoming earnings call on October 28. The fund manager will verify the full pipelines and early news for these stocks and review the results on the specified dates. The fund is currently in research mode only and has not placed any orders.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 21, 2026, at 10:16:05 UTC. The fund reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. It also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the fund looked at RSS feeds from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 15, 2026. The fund also checked the FDA website for information on GRAL, which has a meeting scheduled for September 23, 2026. The fund will review new results on the following dates: September 9 at 12:30 for morning results, September 10 at 12:30 for LOVE, and September 24 at 12:30 for SFIX. The GRAL meeting on September 23 is not for approval. The fund has a strong cash position and will validate records, but it will also reverify weak or early results. No automatic orders were placed.

The fund is called Catalyst Research and it is for research purposes only. The fund size is 0 and the time is 2026-09-21T07:46:05.660192+00:00. There are several news updates from various companies, including TLX on Sunday, September 20, 2026, which can be found at https://telixpharma.com/news-views/telix-and-itm-join-forces-to-create-a-radiopharmaceutical-powerhouse/, AVO on Tuesday, September 8, 2026, which can be found at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial, ABM on Tuesday, September 8, 2026, which can be found at https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results, ROIV on Tuesday, September 8, 2026, which can be found at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat, UNFI on September 14, 2026, with a 10-K filing at 0001020859-26-000025/unfi-20260801.htm, DRI on July 24, 2026, with a 10-K filing at 0000940944-26-000025/dri-20260531.htm, PPIH on September 9, 2026, with a 10-Q filing at 0001437749-26-029988/ppih20260731_10q.htm, MRK on August 7, 2026, with a 10-Q filing at 0000310158-26-000212/mrk-20260630.htm, WLTH on September 14, 2026, with a 10-Q filing at 0001628280-26-061848/wlth-20260731.htm, EPM on Tuesday, September 15, 2026, which can be found at https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-reports-fiscal-fourth-quarter-and-full-0, and IPHA on September 17, 2026, with a 6-K filing at 0001628280-26-062360/a6kseptember172026.htm. There are also HTTP200 hash updates for KGF with a hash of 9ef4336aeb9528cc, ASKUL with a hash of e6f0d85c03a37ce6, IPHAnews with a hash of ef3293fd5ff26cb3, and SOBI with a hash of 7569409d160b2a08. The decision is to preserve monitors 165, 168, 167, 137, and 22, and there are no orders. The research is ongoing, with a note to read originals and validate strong and new information, and to cash and reverify weak, absent, or error information. There is also a note about IPHA on September 17 and Sobi receipt/Q1-2028 conditional.

The Catalyst fund is currently researching IONS, MIRM, GIS, and EAT, with a size of 0. As of September 21, 2026, at 06:46:05 UTC, the fund has noted the following: IONS filed a SEC report on September 4, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/874015/000114036126035802/ef20081690_8k.htm. MIRM filed a SEC report on September 8, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/1759425/000175942526000047/mirm-20260902.htm. GIS filed a SEC report on July 1, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/40704/000162828026046337/gis-20260701.htm. EAT filed a SEC report on September 17, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/703351/000070335126000032/eat-20260917.htm. A discovery was made on September 9, 2026, at 13:12:14Z, where Barclays maintained an overweight rating on Ionis Pharmaceuticals and lowered its price target to $85. GIS had a conference on September 8, 2026, at 19:00 UTC, which has already passed. The fund will review the replay. On September 23, 2026, at 13:00 UTC, GIS will have a Q&A session for its morning earnings report, with the first release time unknown. The fund will review the report at https://investors.generalmills.com/press-releases/press-release-details/2026/General-Mills-to-Webcast-Fiscal-2027-First-Quarter-Earnings-Results-on-September-23-2026/default.aspx. If GIS has stronger organic cash and guidance, the fund will record and validate the results. If the results are weaker or absent, the fund will reverify the cash. There will be no automatic entry, and the dates are for review purposes only, not for first news. The baseline for GIS is a FY27 EPS of $3.00-3.20, with organic growth of -1.5% to +0.5%, and savings of $750 million. The fund had a frozen paper window from September 16 to September 21, with a calendar out-of-sample performance of +0.567% and stress of -2.405%. The fund will never retune past tests. EAT had an investor day on September 17, 2026, from 08:30-11:15 CT, which was reviewed at 16:30 UTC. The fund will also review EAT's earnings call on October 28, 2026, at 16:30 UTC. If EAT has stronger organic cash, the fund will record and independently validate the results. If the results are weaker or absent, the fund will reverify the cash. The fund has a frozen T5 holdout of -19.2065% and will not make any automatic trades. The investor-day odds are untested, and static dates are not armed. The fund has ended its review of 4 SEC reports, 1 discovery, and 2 reports each for GIS and EAT, and will verify the full pipelines and early news. The Catalyst fund is for research purposes only and will not place any orders, as of September 21, 2026, at 06:46:09 UTC.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 21, 2026, at 06:01:14 UTC. The fund reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. It also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the fund looked at RSS feeds from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 15, 2026. The fund also checked the FDA website for information on GRAL, which has a meeting scheduled for September 23, 2026. The fund will review new morning results on September 9 at 12:30, LOVE on September 10 at 12:30, and SFIX on September 24 at 12:30. The GRAL meeting on September 23 is not for approval. The fund has a strong cash position, which will be recorded and validated, while weak or early positions will be cashed out and reverified. No automatic orders were placed.

The fund is called Catalyst Research and it has a size of 0 as of September 21, 2026, at 03:46:03 UTC. There are several news updates from various companies, including Telix Pharma on Sunday, September 20, 2026, which announced a partnership, and Mission Produce, ABM, and Roivant, all of which announced financial results on Tuesday, September 8, 2026. Additionally, there are financial reports from UNFI, DRI, PPIH, MRK, and WLTH, with filing dates ranging from July 24, 2026, to September 14, 2026. Evolution Petroleum also reported its fiscal fourth quarter and full-year results on Tuesday, September 15, 2026. There are also updates from IPHA, with a 6-K filing on September 17, 2026, and several HTTP requests with hashes, including KGF, ASKUL, IPHAnews, and SOBI. The research is marked as'research only' and there are instructions to read originals and validate strong or new information, and to cash and reverify weak, absent, or error information. There is also a note about IPHA on September 17, and a conditional receipt for Sobi in Q1 2028. Certain monitors, including 165, 168, 167, and 137, and 22, are to be preserved. The sources and dates are listed in the job script and journal, and there are no orders.